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An unlicensed medicine is defined as a medicinal product for which there is no marketing authorisation granted by the Medicines Healthcare and Regulatory Agency (MHRA)1.
Unlicensed medicines are widely used within the UK and there are many guidance documents which exist to support their use. However, each guidance document is published 
for individual organisations and there has never been an analysis of the different approaches these documents take nor an evaluation of their quality.
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A systematic search of the published and unpublished literature between 2000 and June 2015. This included:
• A database search including Medline, Embase, ISI Web of Knowledge, Google Scholar, PubMed and 
International Pharmaceutical Abstracts. Search terms included ‘unlicensed medicine’ or ‘specials’ combined 
with; guideline, policy, framework, standardized operating procedure, standard operating procedure or 
recommendation. 
• A ‘call for guidance’ which was distributed to encourage organisations to submit their guidance documentation 
for the review. This was distributed to secondary care, primary care, community pharmacy and pharmaceutical 
industry networks both locally and nationally.
• Website searches for organisations within the North East and North Cumbria Local Clinical Research Network.
Identified documentation included guidance designed to aid professionals within the UK on the use of unlicensed 
medicines, covering areas such as prescribing, procurement, dispensing or administration. Excluded documents 
consisted of those providing specific guidance on homeopathic medicines, food or dietary supplements, herbal 
medicines, radiopharmaceuticals, orphan drugs and investigational medicinal products.
The quality of the guidelines was assessed using the AGREE II tool2. Content was evaluated by conducting a 
thematic analysis. The AGREE ll tool rates the quality of the documentation across six domains and provides a 
score from 0% for very poor quality to 100% for excellent quality. Each guideline was independently assessed by 
two researchers.
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A total of 24,025 documents were screened from a combination of database searching (n=24,025), website searches (n=19) and submissions (n=87). Following application of 
exclusion criteria and removal of duplicates, a total of 52 guidance documents were included in the analysis. This included those from NHS secondary and tertiary care trusts
(n=29), professional bodies and regulators (n=12), community pharmacy and primary care (n=11). Documents included within the analysis ranged from guidelines (n=28), 
policies (n=10), standard operating procedures (n=9) and frameworks (n=5).
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• Both forms of analysis demonstrated a lack of consistency of content and 
quality across guidance documentation used for unlicensed medicines. 
• The AGREE ll scores also exhibit a lack of transparency around who writes 
and updates guidance on unlicensed medicines 
• The lack of evidence base for recommendations is likely to reflect a wider 
issue around lack of evidence for unlicensed medicines use. 
• There is a deficit in patient involvement in guidance
• There was a lack of documentation from community pharmacy and primary 
care. It is not clear if this is due to a lack of guidance or a lack of submission 
to the project.
• Healthcare organisations would benefit from agreeing a ‘core content’ for 
unlicensed medicines documentation
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Average domain scores for each documentation setting can be seen in Figure 2.
Overall the best performing domains were:
• ‘Scope and Purpose’ (70.6%)
• ‘Clarity of Presentation’ (70.4%)
Most documents had specific objectives that were well described. The presentation
of information was good, enabling key recommendations to be easily identified.
The least well performing domains overall were:
• ‘Rigour of Development’ (12.1%)
• ‘Editorial Independence’ (2.6%)
There was a lack of documented references to a clear evidence base. It was not
clear in the majority of cases if there were any funding bodies or competing
interests in the development of the unlicensed guidance documentation.
There was a variation within some of the domains:
• ‘Applicability’ (23.9%)
• ‘Stakeholder Involvement’ (30%)
Whilst some documents provided advice and tools in implementation of the
recommendations, many did not and there was a deficit in the acknowledgement of
the potential barriers and facilitators to implementation of recommendations. For
‘Stakeholder development’ it wasn’t always apparent if there was a diverse mix of
professionals involved in the development of the guidance documentation and there
was little to no involvement of patients.
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Thematic analysis of the guidance documents revealed four parent themes 
across the documentation (see Table 1).
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Parent theme Sub-themes
Responsibility 
around the use 
of unlicensed 
medicines
Understanding the definitions around unlicensed medicines
Awareness of patients and professionals when using an unlicensed medicine
Responsibilities of individuals and organisations involved in using unlicensed 
medicines
References to the guidance and legislation which informed guidance documentation
Operational 
issues with 
using 
unlicensed 
medicines
Selecting the pharmaceutical formulation
Role of the pharmacist and the wider pharmacy team in managing the use of 
unlicensed medicines 
Patient involvement
Stages of using an unlicensed medicine 
Continuing treatment 
Risk versus 
benefit
Evidence to support use of unlicensed medicines 
Place of unlicensed medicines in the treatment of a patient and potential alternatives
Describing and assessing risk 
Reporting of errors and adverse effects associated with unlicensed medicines
Controlling the 
use of 
unlicensed 
medicines
Costs associated with unlicensed medicines
Audit of unlicensed medicines use 
Restricting use of unlicensed medicines 
Organisational decision making surrounding unlicensed medicines
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